Press
Releases
Press Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2020-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Apr 03, 2020
AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact
Patient identification for clinical trials continues; dosing temporarily paused as clinical trial sites focus on COVID-19 pandemic Essential laboratory and manufacturing activities currently uninterrupted Cash runway into Q2 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 30, 2020-- AVROBIO, Inc.
Mar 30, 2020
AVROBIO to Participate in Upcoming April Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual
Mar 26, 2020
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 25, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Mar 25, 2020
AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
Presented positive data at the 16 th Annual WORLD Symposium ™ on AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease, as well as early data on plato™-produced drug product and plasma enzyme activity level Received orphan drug designation from U.S. Food and Drug Administration for AVR‑RD‑04;
Mar 16, 2020
AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan status CAMBRIDGE, Mass. --(BUSINESS WIRE)-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S.
Mar 09, 2020
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of
Mar 05, 2020
AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the Cowen and Company 40 th
Feb 24, 2020
AVROBIO Announces Closing of Underwritten Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock.
Feb 18, 2020
AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share.
Feb 12, 2020
Displaying 1 - 10 of 16